deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT00533949

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer

Sponsor: Cancer and Leukemia Group B

Conditions Lung Cancer Radiation Toxicity
Interventions 60 Gy RT 74 Gy RT Carboplatin Cetuximab Paclitaxel
Updated 14 times since 2017 Last updated: May 23, 2022 Started: Nov 30, 2007 Primary completion: Jun 30, 2013 Completion: May 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lung Cancer and Radiation Toxicity and is currently completed. Cancer and Leukemia Group B leads this study, which shows 14 recorded versions since 2007 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

  5. Dec 2021 — Jul 2022 [monthly]

    Unknown Status PHASE3

▶ Show 9 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  2. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer and Leukemia Group B
  • NRG Oncology
  • National Cancer Institute (NCI)
  • North Central Cancer Treatment Group
  • Radiation Therapy Oncology Group
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Alexandria, United States , Allentown, United States , Amarillo, United States , Ann Arbor, United States , Appleton, United States , Arlington, United States , Atlanta, United States and 164 more locations